Key result
Class IIIA antiarrhythmic agents should ideally lengthen refractoriness upon acceleration of the heart to exceed the cycle length of tachycardia.
Design
Review
Authors
Loading...
May guide rate-dependent Class III agent design; leaves open clinical efficacy in tachyarrhythmias.
This paper proposes theoretical mechanisms for developing ideal Class III antiarrhythmic agents that increase refractoriness during tachycardia rather than bradycardia.
Luc M. Hondeghem (1992) conducted an editorial in Arrhythmia. Class IIIA antiarrhythmic agents was evaluated. Class IIIA antiarrhythmic agents should ideally lengthen refractoriness upon acceleration of the heart to exceed the cycle length of tachycardia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: